Feb 01, 2024
- Corporate
Notice of Partial Amendment to the Articles of Incorporation
Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
President & CEO: | Osamu Okuda |
Inquiries to: | Kae Miyata |
Head of Corporate Communications Dept. | |
Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. (hereafter the “Company”) announces that the Company resolved at the meeting of its Board of Directors held today, to propose an agenda “Partial Amendment to the Articles of Incorporation” at the 113th Annual General Meeting of Shareholders to be held on March 28, 2024 as follows.
- Reasons for the Amendment
The term of office of Directors as stipulated in Article 19 of the current Articles of Incorporation will be changed from 2 years to 1 year to provide greater clarity to the management responsibilities of directors, to increase opportunities for shareholders to express their trust and to build a management system that can promptly adapt to evolving management environments.
- Content of the Amendment
Details of the proposed amendment are as follows:
(Amended parts are underlined.)
Current Proposed Amendment CHAPTER 4
DIRECTORS AND BOARD OF DIRECTORSCHAPTER 4
DIRECTORS AND BOARD OF DIRECTORSArticle 19 (Term of Office of Directors)
The term of office of Directors shall be until the close of the ordinary general meeting of shareholders held with respect to the last business term ending within two (2) years after election.Article 19 (Term of Office of Directors)
The term of office of Directors shall be until the close of the ordinary general meeting of shareholders held with respect to the last business term ending within one (1) year after election. - Schedule
Annual General Meeting of Shareholders to approve the Amendment: March 28, 2024
Effective Date of the Amendment: March 28, 2024
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp